Secarna Pharmaceuticals GmbH & Co. KG

  • Land: Deutschland

Nachricht vom 17.10.2018 | 13:00

Secarna Pharmaceuticals to attend BIO-Europe(R) 2018 - 24th Annual International Partnering Conference

DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Conference

17.10.2018 / 13:00
The issuer is solely responsible for the content of this announcement.


Secarna Pharmaceuticals to attend BIO-Europe(R) 2018 - 24th Annual International Partnering Conference

Munich/Martinsried, Germany, October 17, 2018
- Secarna Pharmaceuticals ("Secarna"), a new breed biopharmaceutical company focusing on the discovery and development of antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets in a number of organ systems, today announced that the Company will participate in the upcoming BIO-Europe(R) 2018 - 24th Annual International Partnering Conference taking place from November 5 to 7, 2018 in Copenhagen, Denmark.

"With entering into a co-development agreement with Firebrand Therapeutics, Inc., a scientifically leading research and development company focusing on cancer metastasis as well as receiving a Horizon 2020 grant for the development of a novel nanomedicine as a partner in the international INAT consortium, we have seen some significant milestones for Secarna over the past months. These further validate our approach to develop highly specific, safety-optimized and efficacious antisense therapies for challenging and previously undruggable targets," said Jonas Renz, Managing Director and Co-founder of Secarna. "We are confident that we are on the right track to write new chapters in the book of antisense oligonucleotides discovery and development and are therefore looking forward to enter into discussions with potential partners and present our achievements to a wide range of industry experts."

Jonas Renz, Secarna's Managing Director and Co-Founder, will be available for one-on-one meetings with interested parties over the course of the conference.

Parties interested in meeting with Secarna Pharmaceuticals at BIO-Europe(R) 2018 are requested to send an invitation through the event's partneringONE(R) partnering software or to contact info@secarna.com. The Company will also be available for media interviews and background discussions.

 

About BIO-Europe(R)

BIO-Europe is the preeminent partnering conference of the European life science industry, bringing together international decision makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities and private one-to-one meetings. The BIO-Europe 2018 partnering event is expected to draw over 4,000 industry attendees for three days of high-level networking, representing upwards of 2,000 companies from over 60 countries. To learn more about the conference, please visit https://ebdgroup.knect365.com/bioeurope/.

 

About Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company with multiple innovative antisense therapies in various stages of pre-clinical development in the areas of immuno-oncology, ophthalmology, immunology, fibrotic diseases (airways, liver, kidney), and anti-viral applications. Secarna's mission is to maximize the performance and output of its proprietary LNAplus(TM) antisense oligonucleotide discovery platform, to develop highly specific, safe, and efficacious antisense therapies for challenging or currently not druggable targets. www.secarna.com

Contact

Jonas Renz
Managing Director and Co-Founder
Jonas.Renz@secarna.com

Secarna Pharmaceuticals GmbH & Co. KG
Am Klopferspitz 19
82152 Planegg/Martinsried
Tel.: +49 (0)89 215 46 375

For media enquiries:

Anne Hennecke
MC Services AG
anne.hennecke@mc-services.eu
Tel.: +49 (0)211.52 92 52 22



17.10.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

Anleihe im Fokus

Deutsche Rohstoff
"Anleihe - Jetzt zeichnen!"

- Emissionsvolumen: bis zu 100 Mio. EUR
- Zeichnungsfrist: 11.11. bis 04.12.2019
- ISIN: DE000A2YN3Q8 / WKN: A2YN3Q
- Börsenesegment: Börse Frankfurt, Open Market (Quotation Board)
- Stückelung / Emissionspreis: 1.000 EUR/ 100%
- Zinssatz (Kupon): 5,25 %
- Laufzeit: 5 Jahre
- Fälligkeit: 5 Jahre / 6.12.2024 (vorbehaltliche vorzeitige Rückzahlung gemäß Anleihebedingungen)
- Zinszahlung: Angebot an Inhaber der 5,625 % Schuldverschreibung 2016/2021 (WKN A2AA05, ISIN DE000A2AA055) diese in die neue Anleihe zu tauschen
- Umtauschfrist: 11.11.2019 – 29.11.2019 (18.00 Uhr)

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

Aktueller Webcast

EQS Group AG

Conference Call zu den Neunmonatszahlen 2019

15. November 2019

Aktuelle Research-Studie

Uzin Utz AG

Original-Research: Uzin Utz AG (von Montega AG): Kaufen

15. November 2019